

TECHNICAL ADVANCE

Open Access



# Multiplex pyrosequencing assay using AdvISER-MH-PYRO algorithm: a case for rapid and cost-effective genotyping analysis of prostate cancer risk-associated SNPs

Jérôme Ambroise<sup>1†</sup>, Valentina Butoescu<sup>2†</sup>, Annie Robert<sup>3</sup>, Bertrand Tombal<sup>2</sup> and Jean-Luc Gala<sup>1\*</sup>

## Abstract

**Background:** Single Nucleotide Polymorphisms (SNPs) identified in Genome Wide Association Studies (GWAS) have generally moderate association with related complex diseases. Accordingly, Multilocus Genetic Risk Scores (MGRSs) have been computed in previous studies in order to assess the cumulative association of multiple SNPs. When several SNPs have to be genotyped for each patient, using successive uniplex pyrosequencing reactions increases analytical reagent expenses and Turnaround Time (TAT). While a set of several pyrosequencing primers could theoretically be used to analyze multiplex amplicons, this would generate overlapping primer-specific pyro-signals that are visually uninterpretable.

**Methods:** In the current study, two multiplex assays were developed consisting of a quadruplex (n=4) and a quintuplex (n=5) polymerase chain reaction (PCR) each followed by multiplex pyrosequencing analysis. The aim was to reliably but rapidly genotype a set of prostate cancer-related SNPs (n=9). The nucleotide dispensation order was selected using SENATOR software. Multiplex pyro-signals were analyzed using the new AdvISER-MH-PYRO software based on a sparse representation of the signal. Using uniplex assays as gold standard, the concordance between multiplex and uniplex assays was assessed on DNA extracted from patient blood samples (n = 10).

**Results:** All genotypes (n=90) generated with the quadruplex and the quintuplex pyrosequencing assays were perfectly (100%) concordant with uniplex pyrosequencing. Using multiplex genotyping approach for analyzing a set of 90 patients allowed reducing TAT by approximately 75% (*i.e.*, from 2025 to 470 min) while reducing reagent consumption and cost by approximately 70% (*i.e.*, from ~ 229 US\$ /patient to ~ 64 US\$ /patient).

**Conclusions:** This combination of quadruplex and quintuplex pyrosequencing and PCR assays enabled to reduce the amount of DNA required for multi-SNP analysis, and to lower the global TAT and costs of SNP genotyping while providing results as reliable as uniplex analysis. Using this combined multiplex approach also substantially reduced the production of waste material. These genotyping assays appear therefore to be biologically, economically and ecologically highly relevant, being worth to be integrated in genetic-based predictive strategies for better selecting patients at risk for prostate cancer. In addition, the same approach could now equally be transposed to other clinical/research applications relying on the computation of MGRS based on multi-SNP genotyping.

**Keywords:** Multiplex, Pyrosequencing, Polymorphisms, Prostate

\*Correspondence: jean-luc.gala@uclouvain.be

†Equal contributors

<sup>1</sup>Center for Applied Molecular Technologies (CTMA), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Clos chapelle-aux-champs B1.30.24, 1200 Brussels, Belgium

Full list of author information is available at the end of the article

## Background

Since 2005, a large number of Genome-Wide Association Studies (GWAS) have identified Single Nucleotide Polymorphisms (SNPs) associated with more than 300 complex diseases and traits [1]. For prostate cancer (PCa), 47 risk-associated SNPs have been identified [2] that are essentially found in 8q24 and 17q chromosomal regions although not strictly restricted to these areas. Most of these SNPs have been tested in large population surveys as stand-alone predictors.

Considering that each SNP has only a moderate association with PCa, Multilocus Genetic Risk Scores (MGRSs) were computed in different studies to assess the cumulative association of multiple SNPs. Zheng et al. assessed the cumulative effect of five selected SNPs [3]. Compared to men without any of these risk genotypes, the odds ratio for PCa was 4.47 (2.93-6.80) in those having four of them or more. Kader et al. computed MGRS based on 33 established PCa risk-associated SNPs and demonstrated the potential added value of the score for PCa risk prediction [4]. More recently, a MGRS computed from a set of nine published SNPs (rs1016343, rs16901979, rs6983267, rs4242382, rs10993994, rs10896449, rs4430796, rs1859962, and rs5945619) improved the performance of a clinical risk-calculator in predicting prostate biopsy result [5]. The predictive performance of the integrated clinico-genetic model (AUC = 0.781) was higher than the predictive performance of the clinical score alone (AUC = 0.770). This set of nine risk-associated SNPs was selected from the breast and prostate cancer cohort consortium (BPC3) results [6], according to reported allelic odds ratio, prevalence and potential linkage disequilibrium.

While approaches for identifying men at high risk of PCa are still needed, the costs of genetic testing are currently too high to perform large-scale screening [7]. Consolidating a broader use of genetic testing in PCa early detection algorithms will require a cheaper and faster though equally high throughput and reliable procedure. Pyrosequencing is a cost-effective DNA sequencing technique that has many applications, including rapid SNP genotyping. The chemiluminescent signal produced during the reaction is detected in the pyrosequencer and displayed in a pyro-signal (*i.e.*, a pyrogram™) which is then translated into the corresponding nucleotide sequence. Usually, genotyping a single SNP is carried out with one separate reaction in one well (*i.e.*, a uniplex experiment). Genotyping of multiple SNPs using uniplex pyrosequencing requires therefore performing multiple simultaneous or successive reactions for each patient, which impacts reagent costs and Turnaround Time (TAT). A more efficient alternative would be to use simultaneously a set of several

pyrosequencing primers in a single well (*i.e.*, a multiplex reaction).

Duplex (n=2) and triplex (n=3) pyrosequencing applications for SNP genotyping were recently developed using LBP [8], CTLA-4 [9], or CYP2C19 [10] target genes. In these applications, nucleotide dispensation orders were carefully selected and successfully avoided overlapping primer-specific signals. However, only one gene with two to three different SNPs were assayed. For some multiplex pyrosequencing applications, overlapping primer-specific signals are unavoidably created and visually uninterpretable. Accordingly, the AdvISER-M-PYRO software was recently and specifically developed to allow the analysis of overlapping pyro-signals generated from multiplex reactions (*i.e.*, the comprehensive set of each peak height characterizing a well-defined pyro-sequence in uniplex experiments or a combination thereof in multiplex experiments) [11, 12]. In parallel, the pyrosequencing nucleotide dispensation order was improved by developing the SENATOR (“SElecting the Nucleotide dispensATIOn Order”) algorithm. AdvISER-M-PYRO is based on the modelling of multiplex pyro-signals as a sparse representation of elements (named atoms) from a standardized learning dictionary that includes corresponding uniplex pyro-signals. The first application of SENATOR and AdvISER-M-PYRO consisted in genotyping alterations underlying bacterial resistance to  $\beta$ -lactam antibiotics [12].

In the present study, two multiplex assays were developed consisting of a quadruplex and a quintuplex PCR, each followed by pyrosequencing analysis for genotyping a set of PCa-related SNPs (n=9) [5]. The dispensation order was selected using SENATOR and multiplex pyro-signals were analyzed with an adapted version of AdvISER-M-PYRO (named AdvISER-MH-PYRO), which integrates a new function allowing bi-allelic SNP genotyping. The analytical reagent costs, waste production and TAT of conventional uniplex and new multiplex pyrosequencing assays were compared.

## Methods

### Patients and DNA extraction

Both multiplex pyrosequencing assays were developed and validated on DNA extracted from patient blood (n = 10). These patients had been included in a previous study [5] and provided informed consent, following approval of the study by the Ethics Committee (Comité d’Éthique Hospitalo-Facultaire, Cliniques Universitaires Saint-Luc - Université Catholique de Louvain, Brussels). The extraction of genomic DNA was performed from peripheral blood lymphocytes using the EZ1 DNA Blood kit and BioRobot EZ1 (Qiagen, Leusden, The Netherlands), according to the manufacturer’s protocol.

### Selection of the pyrosequencing dispensation order

A list of all unique nucleotide sequence (UNS) expected to be found in the 9 selected genomic regions was compiled (Table 1). Considering that pyrosequencing experiments were designed with reverse primers for some SNPs (Tables 1 and 2), the complementary sense sequence was computed for the corresponding UNS. Allocation of each of the nine SNPs either to quadruplex or quintuplex assay was made according to optimal PCR conditions commonly used for individual SNP genotyping. Then, the SENATOR [12] function was used to generate a suitable nucleotide dispensation order for both quadruplex and the quintuplex assays.

### Uniplex and multiplex PCR and pyrosequencing

Identification of the nine SNPs was first carried out for all patients (n=10) using uniplex (n=9) PCRs, followed by uniplex pyrosequencing reactions (n=9). All genotypes (n=90) resulting from uniplex pyro-signals were used as gold standard.

In the following steps, quadruplex PCR followed by quadruplex pyrosequencing was carried out on four SNPs, while quintuplex PCR followed by quintuplex pyrosequencing was carried out on the remaining five SNPs (Table 1). Although protocols for individual SNP genotyping differed initially in terms of MgCl<sub>2</sub> concentration (2.25 or 3.0 mM) and number of PCR cycles (35 or 40),

subsequent condition testing allowed to standardize the PCR multiplex protocol.

Multiplex PCR was carried out in a 50  $\mu$ L reaction mixture containing 7 or 10  $\mu$ L (for quadruplex and quintuplex assays, respectively) of the extracted DNA (50 ng), 5  $\mu$ L of a PCR buffer (100 mM Tris hydrochloride, and 500 mM potassium chloride, pH 8.3), 3mM MgCl<sub>2</sub>, 1U AmpliTaq Gold<sup>®</sup> DNA Polymerase (AmpliTaq Gold<sup>®</sup> DNA Polymerase kit from Applied Biosystems<sup>®</sup>, Austin, USA), 200 $\mu$ M of each deoxynucleotide triphosphate (dNTPs: dATP, dCTP, dGTP, dTTP Li-salts from Roche Diagnostics GmbH, Mannheim, Germany) and forward and reverse PCR primers (Table 1) (Eurogentec, Liège, Belgium). Amplification was performed in a 2720 Thermal Cycler (Applied Biosystems<sup>®</sup>) using the following conditions: 95 °C for 5 minutes, followed by 40 cycles with denaturation at 95 °C for 40 seconds, annealing at 60 °C for 40 seconds, and extension at 72 °C for 80 seconds, with a final extension step at 72 °C for 7 minutes. Electrophoresis of PCR products was performed on 2% agarosis gel. Pyrosequencing was then carried out with a pyrosequencer PyroMark PSQ 96 MA Sequencer from Qiagen (Hilden, Germany) on PCR products, using a mixture of the pyrosequencing primers (0.4 $\mu$ M each) (Table 2), enzymes and substrate (PyroMark Gold<sup>®</sup> Q96 Reagents kit, Qiagen) according to the manufacturer's protocol. Each PCR and pyrosequencing

**Table 1** List of selected SNPs (n=9) and their corresponding MAF, OR and UNS

| SNP        | Chromosome | Allelic OR <sup>a</sup> | MAF <sup>a</sup> | Unique Nucleotide Sequences (UNS) | Forward Reverse | Quadruplex(n=4) Quintuplex (n=5) |
|------------|------------|-------------------------|------------------|-----------------------------------|-----------------|----------------------------------|
| rs1016343  | 8          | 1.25                    | 0.21             | TTCCCTCCCA<br>TTCCCTCTCA          | Reverse         | 4                                |
| rs10993994 | 10         | 1.23                    | 0.47             | TGACGTCGAA<br>TGATGTCGAA          | Forward         | 4                                |
| rs16901979 | 8          | 1.44                    | 0.18             | ATCTGGCAAA<br>CTCTGGCAAA          | Forward         | 4                                |
| rs5945619  | X          | 1.23                    | 0.26             | ACTCCCGCCG<br>ACTCCCGCTG          | Reverse         | 4                                |
| rs10896449 | 11         | 0.84                    | 0.4              | GCTGAAAATT<br>GCTGAAAGTT          | Reverse         | 5                                |
| rs1859962  | 17         | 1.19                    | 0.39             | TGATGAACAC<br>GGATGAACAC          | Forward         | 5                                |
| rs4242382  | 8          | 1.4                     | 0.16             | CCACAGGCCC<br>CCGCAGGCCC          | Forward         | 5                                |
| rs4430796  | 17         | 0.8                     | 0.46             | GATGCTGCAT<br>AATGCTGCAT          | Forward         | 5                                |
| rs6983267  | 8          | 0.81                    | 0.43             | TGAAAGGCAC<br>TGAAAGTCAC          | Reverse         | 5                                |

<sup>a</sup>OR: Odds Ratio, MAF = Minor Allele Frequency

**Table 2** PCR and pyrosequencing primers and primer concentrations for each selected SNP before and after concentration adjustment

| SNP        | Quadruplex (n=4)<br>Quintuplex (n=5) | Multiplex PCR                          |                      |                       | Multiplex PYRO             |                 |
|------------|--------------------------------------|--|----------------------|-----------------------|----------------------------|-----------------|
|            |                                      | Primer                                 | Conc.( $\mu$ M)      |                       | Primer                     | Conc.( $\mu$ M) |
|            |                                      |  | Initial <sup>a</sup> | Adjusted <sup>a</sup> |                            |                 |
| rs1016343  | 4                                    | F: 5'-Biot-TCAGGGCAATTACGGAATAACA-3'   | 0.1                  | 0.1                   | 5'-TGAAGCTGTGAGTAATCA-3'   | 0.4             |
|            |                                      | R: 5'-AATCTAAAGAATGGGGTCAGAG-3'        | 0.1                  | 0.1                   |                            |                 |
| rs10993994 | 4                                    | F: 5'-CTCTCCTCCTCTGCTCTTTTAGGT-3'      | 0.1                  | 0.1                   | 5'-TTGTTATCATTCCCAA-3'     | 0.4             |
|            |                                      | R: 5'- Biot- AGGCAAAGCTGCATCAAAC-3'    | 0.1                  | 0.1                   |                            |                 |
| rs16901979 | 4                                    | F: 5'-GTGGGGTCTTTGTTGTGGA-3'           | 0.1                  | 0.1                   | 5'-AATGATTTAGCATTACTTAT-3' | 0.4             |
|            |                                      | R: 5'-Biot-TTATGTTCCAGAGCGGTTGAATG-3'  | 0.1                  | 0.1                   |                            |                 |
| rs5945619  | 4                                    | F: 5'-Biot-CAGGAAGGGGAACATCACACT-3'    | 0.1                  | 0.05                  | 5'-CTTGCGGGAGTCTCA-3'      | 0.4             |
|            |                                      | R: 5'- ACGGCTACTATGAGATGAGGAAAC-3'     | 0.1                  | 0.05                  |                            |                 |
| rs10896449 | 5                                    | F: 5'-Biot-GGGCCACAGGAACAA-3'          | 0.1                  | 0.15                  | 5'-TGACATTCCCCTTCTTA-3'    | 0.4             |
|            |                                      | R: 5'-GCCTTTTCAATGAACCCACA-3'          | 0.1                  | 0.15                  |                            |                 |
| rs1859962  | 5                                    | F: 5'-AATAAGAGGCTGCAGACTTTTCC-3'       | 0.1                  | 0.05                  | 5'-AAATCCCTGCCCCGTG-3'     | 0.4             |
|            |                                      | R: 5'-Biot-TAGGCATTCCAAGATGAAGACTC-3'  | 0.1                  | 0.05                  |                            |                 |
| rs4242382  | 5                                    | F: 5'-AAAAGAGGTAACCCAGGGAACA-3'        | 0.1                  | 0.075                 | 5'-TTGTCCCTCTAGTTATCTTC-3' | 0.4             |
|            |                                      | R: 5'-Biot-GCATAGAGGGACGCTGTCAA-3'     | 0.1                  | 0.075                 |                            |                 |
| rs4430796  | 5                                    | F: 5'-ACGTCCCTTCTCAGCATCTT-3'          | 0.1                  | 0.3                   | 5'-GGCAGCACAGACTGGA-3'     | 0.4             |
|            |                                      | R: 5'-Biot-TGTTCCCTGACATGAAGCAACTCT-3' | 0.1                  | 0.3                   |                            |                 |
| rs6983267  | 5                                    | F: 5'-Biot-TCTTCCTATCTCAGCTCCCTATCC-3' | 0.1                  | 0.1                   | 5'-AATTCTTTGTACTTTTCTCA-3' | 0.4             |
|            |                                      | R: 5'-GTTGGCTGGCACTGTCTGT-3'           | 0.1                  | 0.1                   |                            |                 |

<sup>a</sup>For each SNP, the concentrations of PCR primers were adjusted in order to select the best conditions for balancing the respective contribution of each SNP in multiplex pyro-signals

reaction included a negative control. All uniplex and multiplex pyrosequencing reactions were carried out with the selected dispensation orders. They were also compared in terms of analytical reagent costs, production of waste material and TAT.

**Multiplex pyro-signal processing using AdvISER-MH-PYRO**

All multiplex pyro-signals were converted into their corresponding genotypes in three successive steps, as described below. Firstly, two standardized learning dictionaries were created, one for the quadruplex, the other for the quintuplex assay. Each dictionary includes a uniplex theoretical pyro-signal for each genotype expected to be found within each genomic region. Aside of the theoretical uniplex pyro-signals (*i.e.*, 7 and 10 in the quadruplex and quintuplex assay, respectively), those generated by uniplex pyrosequencing were also included in both dictionaries. These experimental uniplex pyro-signals were standardized by dividing all peak heights by the corresponding first unitary peak height (FUPH), as previously recommended [12].

In a second step, each multiplex pyro-signal was analyzed with AdvISER-MH-PYRO software. While not included with the previous AdvISER-M-PYRO version which was dedicated to bacterial DNA genotyping, a new feature was implemented into AdvISER-MH-PYRO in order to carry out bi-allelic SNP genotyping. For these SNPs, the pyro-signal generated by a heterozygous variant results from the superposition of pyro-signals generated by both corresponding homozygous allelic variants which, as expected, disclose peak heights twice higher than their heterozygous counterparts (Fig. 1). When the contribution of each homozygous and heterozygous variant is computed for a bi-allelic SNP, a correction factor is then applied by the AdvISER-MH-PYRO version, taking this effect into account.

AdvISER-MH-PYRO was implemented in an R package ([www.uclouvain.be/ctma.html](http://www.uclouvain.be/ctma.html)) that can be applied to analyze multiplex signals generated in a broad range of human SNP genotyping applications.

In a final step, the optimal primer concentration was adjusted for each SNP of both multiplex assays. Accordingly, multiplex PCR and pyrosequencing reactions were first carried out with an initial PCR primer concentration (0.1 μM for each SNP) on a first subset of patients (n=3), and contributions of each SNP to the global multiplex pyro-signal were computed with AdvISER-MH-PYRO. Concentrations of PCR primers were then adjusted in order to select the best conditions for balancing the respective contribution of each SNP in multiplex pyro-signals (Table 2).


**Interoperability of the dictionary**

Considering that the multiplex pyrosequencing approach, as described in this study, requires building a standardized dictionary based on experimental uniplex pyro-signals, an essential feature of the method appears therefore the interoperability of this dictionary for analyzing multiplex pyro-signals generated by different pyrosequencers. Accordingly, multiplex (quadruplex and quintuplex) pyro-signals generated with the PyroMark Q96 ID sequencer, Qiagen (Hilden, Germany), were analyzed using the same dictionary and AdvISER-PYRO software and compared to original results generated by PyroMark Q96MA.

**Results and discussion**

**Selection of the nucleotide dispensation order**

SENATOR was used to select a dispensation allowing to differentiate between all UNSs of interest for the current application (Table 1). Nucleotide dispensation orders with 14 (CTGCATGACTCGAT) and 15 (AGATCGCTACGACTG) nucleotides were selected



for the quadruplex and quintuplex assays, respectively. They generated theoretical uniplex pyro-signals with low pairwise correlation coefficients, avoiding collinearity between signals which are contained in the dictionary and used as predictors in the penalized regression models within the AdvISER-MH-PYRO function.

For both multiplex assays, the theoretical multiplex signals corresponding to all possible combinations of genotypes were generated. The maximum values of the pairwise correlation coefficients between all multiplex signals were equal to 0.9891 and 0.9892 for the quadruplex and quintuplex assays, respectively. Therefore, the selected dispensation orders proved to generate a specific and unique multiplex pyro-signal for each genotypic combination.

**Uniplex pyrosequencing**

Uniplex pyro-signals of all DNA samples (n=10) were obtained with the nucleotide dispensation order corresponding to the quadruplex or quintuplex SNP allocation, and used as gold standard genotype (Table 3).

**Adjustment of PCR primer concentration**

Regarding the quadruplex pyro-signals before primer adjustment, the average relative signal contribution of rs5945619 was higher (35.3 %) than the three other SNPs (15.9 %, 27.4 % and 21.4 % for rs1016343, rs10993994 and rs16901979, respectively). The primer concentration for rs5945619 was therefore decreased (Table 2).

Regarding the quintuplex pyro-signals before primer adjustment, the average relative signal contribution of rs4430796 (5.8 %) and of rs10896449 (10.1 %) were smaller than rs6983267 (21.6 %), while the average relative signal contributions of the two remaining SNPs were significantly higher (35.6 % for rs1859962 and 25.9 % for rs4242382). The primer concentration was therefore

increased for rs4430796 and rs10896449 and decreased for rs1859962 and rs4242382 (Table 2).

**Multiplex PCR and multiplex pyrosequencing**

Multiplex pyrosequencing was carried out on PCR products produced with adjusted PCR primer concentrations. Gel electrophoresis of the quadruplex and quintuplex PCR products is displayed in Fig. 2. Given the similar sizes of the amplification products for the five analyzed SNPs in the quintuplex PCR (rs6983267 : 295 bp, rs1859962 : 177 bp, rs10896449 : 274 bp, rs4430796 : 254 bp, rs4242382 : 250 bp), only 3 bands were present on the gel (samples 1-4). Regarding the quadruplex PCR (samples 5-8), the picture of the electrophoresis gel shows 4 bands, corresponding to the amplification products for rs1016343 (279 bp), rs10993994 (250 bp), rs5945619 (234 bp) and rs16901979 (191 bp), respectively.


All pyro-signals were analyzed using AdvISER-MH-PYRO. For the quadruplex assay, the average relative signal contribution of rs5945619 (17.2 %) decreased and approached the respective contribution of the other three SNPs (18.1 % for rs1016343, 16.9 % for rs10993994, and 47.7 % for rs16901979) (Table 4).

For the quintuplex assay, the average contribution of rs4430796 (12.6 %) and rs10896449 (19.3 %) were increased while the contribution of rs1859962 (16.6 %) was significantly decreased and approached the contributions of the remaining SNPs (24.4 % for rs6983267 and 26.7 % for rs4242382) (Table 5).

Although the contribution of all SNPs was not perfectly balanced in both assays, all genotypes (n=90) generated with the quadruplex (Table 4) and quintuplex (Table 5) assays were perfectly (100 %) concordant with uniplex pyrosequencing results (Table 3). Moreover, all results were associated with a high confidence index (r>0.997). Accordingly, PCR primer concentrations were not further adjusted.

**Table 3** Individual genotype (n=10) for selected SNPs (n=9)

| Patient | rs1016343 | rs10993994 | rs16901979 | rs5945619 | rs10896449 | rs1859962 | rs4242382 | rs4430796 | rs6983267 |
|---------|-----------|------------|------------|-----------|------------|-----------|-----------|-----------|-----------|
| 1       | C/C       | T/T        | C/C        | T         | G/G        | G/G       | G/G       | A/A       | G/T       |
| 2       | C/C       | C/C        | C/C        | T         | A/G        | T/T       | G/G       | A/A       | G/T       |
| 3       | C/C       | C/C        | C/C        | C         | A/G        | T/T       | G/G       | G/G       | G/T       |
| 4       | C/C       | C/C        | C/C        | T         | A/G        | T/G       | G/G       | A/A       | G/G       |
| 5       | C/C       | C/T        | C/C        | T         | G/G        | T/T       | G/G       | G/A       | T/T       |
| 6       | T/T       | C/T        | C/C        | T         | A/G        | T/T       | G/G       | G/A       | T/T       |
| 7       | C/C       | C/T        | C/C        | T         | A/G        | T/G       | G/G       | G/A       | G/G       |
| 8       | C/T       | C/T        | A/A        | T         | A/A        | T/T       | G/G       | A/A       | G/T       |
| 9       | C/C       | C/C        | C/C        | C         | G/G        | T/T       | A/G       | G/A       | T/T       |
| 10      | C/C       | C/C        | C/C        | T         | A/G        | G/G       | G/G       | G/A       | G/T       |



**Fig. 2** Picture of electrophoresis gel of amplification products obtained with 3 DNA samples and 1 negative control, for the quintuplex (samples 1-4) and quadruplex (samples 5-8) PCR, respectively

### Illustration of AdvISER-MH-PYRO

Figure 3 illustrates the results obtained with AdvISER-MH-PYRO when applied on quadruplex (left) and quintuplex (right) pyro-signals generated for the first patient. Both signals are correctly converted into four and five genotypes, respectively.

In both cases, the high confidence index ( $R=0.998$  for quadruplex,  $R>0.999$  for quintuplex) traduces the quasi perfect correlation between the observed multiplex pyro-signal (vertical black lines) and the sparse regression model (colored boxes). As illustrated in Fig. 3, colored boxes, which result from software analysis, fit quasi perfectly the vertical black lines representing the global multiplex pyro-signal produced by the pyrosequencer.

### Interoperability of the dictionary

Irrespective of the equipment used to carry out the pyrosequencing analysis, all genotypes generated with the quadruplex and quintuplex assays were perfectly (100%) concordant with gold standard results as reported in Table 3.

### Impact on analytical reagent costs, production of waste material and TAT

TAT of uniplex and multiplex methods were also compared. Considering that each PCR and pyrosequencing plates includes 96 wells and that negative controls are required, the comparison was performed on a hypothetical set of 90 patients. Whereas buffy coat, DNA extraction and quantification (30, 30 and 20 min, respectively) were identical for both methods, the estimated TAT of PCR (i.e., 165 min) and pyrosequencing (i.e., 60-70 min) carried out in 9 uniplex versus 2 multiplex analyses, was 2025 ( $[165 + 60] \times 9$ ) versus 470 ( $[165 + 70] \times 2$ ) min, respectively.

Analytical costs for analyzing 9 SNPs with the classical uniplex and multiplex pyrosequencing approach

were  $\sim 229$  and  $\sim 64$  US\$/patient, respectively (Table 6).

Using the multiplex approach resulted in an important reduction of waste material produced ( $\sim 75\%$  less than the uniplex method), in terms of quantities of PCR and pyrosequencing plates, pipette tips and reagent bottles (Table 7).

### Conclusions

The present proof-of-concept study aimed to demonstrate the feasibility of SNP multiplex pyrosequencing with the new AdvISER-MH-PYRO algorithm and to assess its impact in terms of cost, TAT and waste material. In this respect, a combination of two multiplex pyrosequencing assays was developed to test in two runs a set of nine prostate cancer-related SNPs. Appropriate nucleotide dispensation orders were selected with the SENATOR function which considers all UNS expected to be found within each genomic region of interest in order to produce uncorrelated uniplex pyrosequencing signals. Multiplex pyro-signals were then analyzed with a new algorithm developed by our team (AdvISER-MH-PYRO). All quadruplex and quintuplex pyro-signals were converted into 4 and 5 genotypes, respectively.

To the best of our knowledge, it is the first time that quadruplex and quintuplex pyro-signals from amplicons generated by a multiplex PCR amplification in a single well are translated into their respective single counterpart and that bi-allelic variants of each target gene are simultaneously identified and assigned. All multiplex results were perfectly (100%) concordant with uniplex results. The latter were taken as gold-standard in this study, considering that uniplex pyrosequencing distinguishes reliably the specific pattern associated with each of the various genotypes, providing therefore accurate typing results [13], as confirmed in previous studies comparing pyrosequencing

**Table 4** Quadruplex (n=4) pyro-signals (n=10): results of AdvISER-MH-PYRO after adjustment of primer concentrations

| Patient | rs1016343 |                               | rs10993994 |                               | rs16901979 |                               | rs5945619 |                               | R <sup>a</sup> |
|---------|-----------|-------------------------------|------------|-------------------------------|------------|-------------------------------|-----------|-------------------------------|----------------|
|         | Genotype  | Contribution <sup>a</sup> (%) | Genotype   | Contribution <sup>a</sup> (%) | Genotype   | Contribution <sup>a</sup> (%) | Genotype  | Contribution <sup>a</sup> (%) |                |
| 1       | C/C       | 4.36 (18.6)                   | T/T        | 2.87 (12.2)                   | C/C        | 11.35 (48.4)                  | T         | 4.85 (20.7)                   | 0.999          |
| 2       | C/C       | 5.52 (20.5)                   | C/C        | 7.05 (26.2)                   | C/C        | 10.71 (39.8)                  | T         | 3.66 (13.6)                   | 0.998          |
| 3       | C/C       | 4.58 (19.6)                   | C/C        | 3.66 (15.6)                   | C/C        | 11.09 (47.4)                  | C         | 4.09 (17.5)                   | 0.999          |
| 4       | C/C       | 2.85 (16.4)                   | C/C        | 2.23 (12.8)                   | C/C        | 9.78 (56.1)                   | T         | 2.57 (14.7)                   | 0.999          |
| 5       | C/C       | 4.97 (18.8)                   | C/T        | 5.34 (20.2)                   | C/C        | 10.63 (40.3)                  | T         | 5.44 (20.6)                   | 0.999          |
| 6       | T/T       | 3.92 (16.3)                   | C/T        | 4.93 (20.5)                   | C/C        | 10.2 (42.5)                   | T         | 4.95 (20.6)                   | >0.999         |
| 7       | C/C       | 3.98 (17.9)                   | C/T        | 3.87 (17.4)                   | C/C        | 10.23 (45.9)                  | T         | 4.2 (18.9)                    | 0.997          |
| 8       | C/T       | 4.87 (18.3)                   | C/T        | 5.19 (19.5)                   | A/A        | 12.41 (46.6)                  | T         | 4.18 (15.7)                   | 0.999          |
| 9       | C/C       | 3.05 (18.4)                   | C/C        | 1.82 (11.0)                   | C/C        | 9.18 (55.3)                   | C         | 2.56 (15.4)                   | 0.999          |
| 10      | C/C       | 2.72 (16.2)                   | C/C        | 2.35 (14.0)                   | C/C        | 9.29 (55.2)                   | T         | 2.46 (14.6)                   | >0.999         |
| Average |           | 18.1                          |            | 16.9                          |            | 47.7                          |           | 17.2                          |                |


<sup>a</sup>For each patient, the genotype and its absolute and relative contributions to the global signal are computed by AdvISER-MH-PYRO for each SNP, R: confidence index traducing the correlation between the observed multiplex pyro-signal and the sparse regression model constructed by AdvISER-MH-PYRO



**Table 5** Quintuplex (n=5) pyro-signals (n=10): results of AdvISER-MH-PYRO after adjustment of primer concentrations

| Patient | rs10896449 |                              | rs1859962 |                               | rs4242382 |                               | rs4430796 |                               | rs6983267 |                               | R     |
|---------|------------|------------------------------|-----------|-------------------------------|-----------|-------------------------------|-----------|-------------------------------|-----------|-------------------------------|-------|
|         | Genotype   | Contriution <sup>a</sup> (%) | Genotype  | Contribution <sup>a</sup> (%) | Genotype  | Contribution <sup>a</sup> (%) | Genotype  | Contribution <sup>a</sup> (%) | Genotype  | Contribution <sup>a</sup> (%) |       |
| 1       | G/G        | 5.51 (19.4)                  | G/G       | 8.79 (30.9)                   | G/G       | 5.75 (20.2)                   | A/A       | 3.24 (11.4)                   | G/T       | 5.13 (18.1)                   | 0.998 |
| 2       | A/G        | 5.82 (23.2)                  | T/T       | 4.05 (16.1)                   | G/G       | 6.91 (27.5)                   | A/A       | 2.33 (9.3)                    | G/T       | 6.00 (23.9)                   | 0.998 |
| 3       | A/G        | 5.67 (21.0)                  | T/T       | 3.96 (14.7)                   | G/G       | 7.63 (28.3)                   | G/G       | 3.31 (12.3)                   | G/T       | 6.40 (23.7)                   | 0.999 |
| 4       | A/G        | 5.07 (20.6)                  | T/G       | 3.50 (14.2)                   | G/G       | 6.44 (26.1)                   | A/A       | 3.30 (13.4)                   | G/G       | 6.36 (25.8)                   | 0.996 |
| 5       | G/G        | 5.55 (19.3)                  | T/T       | 3.52 (12.2)                   | G/G       | 7.74 (26.9)                   | G/A       | 3.14 (10.9)                   | T/T       | 8.86 (30.8)                   | 0.999 |
| 6       | A/G        | 7.28 (22.4)                  | T/T       | 4.91 (15.1)                   | G/G       | 7.47 (23.0)                   | G/A       | 5.21 (16.0)                   | T/T       | 7.64 (23.5)                   | 0.998 |
| 7       | A/G        | 6.35 (21.1)                  | T/G       | 4.28 (14.2)                   | G/G       | 8.22 (27.3)                   | G/A       | 4.28 (14.2)                   | G/G       | 7.00 (23.2)                   | 0.996 |
| 8       | A/A        | 0.94 (10.7)                  | T/T       | 1.47 (16.7)                   | G/G       | 2.82 (32.1)                   | A/A       | 1.57 (17.9)                   | G/T       | 1.99 (22.6)                   | 0.998 |
| 9       | G/G        | 4.73 (18.6)                  | T/T       | 4.43 (17.4)                   | A/G       | 6.80 (26.8)                   | G/A       | 2.17 (8.5)                    | T/T       | 7.27 (28.6)                   | 0.997 |
| 10      | A/G        | 4.23 (14.5)                  | G/G       | 3.07 (14.5)                   | G/G       | 6.15 (29.1)                   | G/A       | 2.50 (11.8)                   | G/T       | 5.16 (24.4)                   | 0.999 |
| Average |            | (19.3)                       |           | (16.6)                        |           | (26.7)                        |           | (12.6)                        |           | (24.4)                        |       |

<sup>a</sup>For each patient, the genotype and its absolute and relative contributions to the global signal are computed by AdvISER-MH-PYRO for each SNP, R: confidence index traducing the correlation between the observed multiplex pyro-signal and the sparse regression model constructed by AdvISER-MH-PYRO



**Fig. 3** Example of a quadruplex (left) and quintuplex (right) pyro-signal identification with AdvISER-MH-PYRO. The multiplex pyro-signal generated by the pyrosequencing machine is displayed before (top) and after (bottom) the analysis. In both cases, it is represented by vertical black lines. After analysis, the contribution of each atom (i.e., each uniplex pyro-signal within the dictionary) is represented by colored boxes stacked on top of the other

versus Sanger sequencing [14, 15]. The analytical reagent costs, waste production and TAT of conventional uniplex and new multiplex pyrosequencing assays were compared. The new multiplex approach allowed to lower costs and waste material production by ~ 70 % and ~ 75 %, respectively. In an era where research laboratories strive to be more environmentally-friendly, this new multiplex method could therefore contribute to minimize waste disposal and footprint. The comparison of TAT was also clearly in favor of the multiplex approach. TAT was indeed reduced by ~ 75 %, without any compromise on results

**Table 6** Analytical reagent costs (US \$)

|                | Uniplex (n=9) | Quadruplex (n=1)<br>+Quintuplex (n=1) |
|----------------|---------------|---------------------------------------|
| DNA extraction | ~ 16.5        | ~ 16.5                                |
| PCR            | ~ 71.0        | ~ 16.0                                |
| Pyrosequencing | ~ 141.5       | ~ 31.5                                |
| TOTAL          | ~ 229.0       | ~ 64.0                                |

quality and reliability and despite a multiplex pyrosequencing run being 10 min longer due to a higher number of dispensed nucleotides.

While uniplex SNP pyrosequencing does not compete with faster and more cost-effective methods (TaqMan [16] or Sequenom [17]), current improvements enabling multiplexing makes it a suitable alternative to the latter methods in terms of TAT, cost and waste production. Although not assessed in this study, in-del could

**Table 7** Waste material produced for a full 96-well plate

|  | Uniplex (n=9) | Quadruplex (n=1)<br>+ Quintuplex (n=1) |
|--|---------------|--|
| PCR plates (n)   | 9             | 2                                      |
| Pipette tips - PCR (n)                                 | 936           | 222                                    |
| Pyrosequencing plates (n)                              | 9             | 2                                      |
| Pipette tips - pyrosequencing (n)                      | 918           | 211                                    |
| Bottles pyrosequencing reagents (enzyme+substrate) (n) | 18            | 4                                      |

also be genotyped in a multiplex experiment with the AdvISER-MH-PYRO algorithm.

Considering that the AdvISER-MH-PYRO software and both dictionaries are available in the corresponding package ([www.uclouvain.be/ctma.html](http://www.uclouvain.be/ctma.html)), and that PCR conditions have already been optimized, these new assays can also easily be implemented in other laboratories now. As evidenced by this study, multiplexing has proved to be particularly relevant when developing new rapid, robust, reliable, cleaner and cost-effective SNP genotyping assays. While the added clinical value of MGRS based on 9 PCa risk-associated SNPs proved indeed not bring a major benefit as previously discussed [5], it was technologically interesting to repeat this SNP analysis using the multiplex pyrosequencing method, especially because this method is widely applicable to a range of other clinical and/or research applications, all relying also on MGRS computation, and therefore requiring multi-SNP genotyping for each patient. Such applications are currently developed in a wide range of diseases, including coronary heart disease [18], liver diseases [19] and acute lymphoblastic leukemia [20]. For these, the methodology reported in this paper is implementable subject to optimization of primers concentration, to building a standardized uniplex pyrosignals-based dictionary and to carrying out multiplex signal analysis with the newly available AdvISER-MH-PYRO function.

#### Competing interests

The authors declare that they have no competing interests.

#### Authors' contributions

JA, VB and JLG designed the study. JA developed the AdvISER-MH-PYRO software. VB achieved all pyrosequencing experiments and compared TAT and reagent costs. JA, VB and JLG participated at the whole writing process. AR supervised the statistical analysis component of the work. BT and JLG supervised the work. BT and AR assisted in finalization of the completed manuscript. All authors read and approved the final manuscript.

#### Acknowledgement

The authors are thankful to Anne-France Dekairelle and Michel Heusterspreute for their technical support and for their help in primer designing.

#### Author details

<sup>1</sup>Center for Applied Molecular Technologies (CTMA), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Clos chapelle-aux-champs B1.30.24, 1200 Brussels, Belgium. <sup>2</sup>Service d'Urologie, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, 1200, Brussels, Belgium. <sup>3</sup>Epidemiology and Biostatistics Department (EPID), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, 1200 Brussels, Belgium.

Received: 12 September 2014 Accepted: 4 June 2015

Published online: 25 June 2015

#### References

- Manolio TA. Bringing genome-wide association findings into clinical use. *Nat Rev Genet.* 2013;14(8):549–58.
- Goh CL, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Thomas K, Selvadurai ED, Woode-Amisshah R, Dadaev T, Mahmud N, Castro E, et al. Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (snp) profiles in an active surveillance cohort. *BJU International.* 2013;112(5):666–73.
- Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami H-O, Hsu F-C, Zhu Y, Bälter K, et al. Cumulative association of five genetic variants with prostate cancer. *N Engl J Med.* 2008;358(9):910–9.
- Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, et al. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the reduce trial. *Eur Urol.* 2012;62(6):953–61.
- Butoescu V, Ambroise J, Stainier A, Dekairelle AF, Gala JL, Tombal B. Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator? *The Prostate.* 2014;74(4):365–71.
- Lindstrom S, Schumacher F, Siddiq A, Travis RC, Campa D, Berndt SI, Diver WR, Severi G, Allen N, Andriole G, et al. Characterizing associations and snp-environment interactions for gwas-identified prostate cancer risk markers - results from bpc3. *PLoS One.* 2011;6(2):17142.
- Martin AJ, Lord SJ, Verry HE, Stockler MR, Emery JD. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis. *Med J Aust.* 2013;198(10):546–0.
- Zeng L, Yu J, Gu W, Zhang A-q, Yue C-l, Chen K-h, Jiang J-x. Rapid genotyping of three polymorphisms in the lbp gene using a triplex pyrosequencing approach. *J Microbiol Methods.* 2013;94(3):300–2.
- Banelli B, Morabito A, Laurent S, Piccioli P, Dozin B, Ghio M, Ascierio PA, Monteghirfo S, Marasco A, Ottaviano V, et al. A novel multiplex pyrosequencing assay for genotyping functionally relevant ctla-4 polymorphisms: Potential applications in autoimmunity and cancer. *Hum Immunol.* 2014;75(8):730–39.
- Kim KA, Song WK, Kim KR, Park JY. Assessment of cyp2c19 genetic polymorphisms in a korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the cyp2c19\* 2, cyp2c19\* 3, and cyp2c19\* 17 alleles. *J Clin Pharm Ther.* 2010;35(6): 697–703.
- Ambroise J, Piette AS, Delcorps C, Rigouts L, de Jong BC, Irengre L, Robert A, Gala JL. Adviser-pyro: amplicon identification using sparse representation of pyrosequencing signal. *Bioinformatics.* 2013;29(16): 1963–1969.
- Ambroise J, Deccache Y, Irengre L, Savov E, Robert A, Gala JL. Amplicon identification using sparse representation of multiplex pyrosequencing signal (adviser-m-pyro): Application to bacterial resistance genotyping. *Bioinformatics.* 2014;30(24):3590–97.
- Ronaghi M. Pyrosequencing sheds light on dna sequencing. *Genome Res.* 2001;11(1):3–11.
- Saeki M, Saito Y, Jinno H, Tohkin M, Kurose K, Kaniwa N, Komamura K, Ueno K, Kamakura S, Kitakaze M, et al. Comprehensive ugt1a1 genotyping in a japanese population by pyrosequencing. *Clinical chemistry.* 2003;49(7):1182–5.
- Koontz DA, Huckins JJ, Spencer A, Gallagher ML. Rapid detection of the cyp2a6\* 12 hybrid allele by pyrosequencing\* technology. *BMC Med Genet.* 2009;10(1):80.
- Francisco M, Lazaruk KD, Rhodes MD, Wenz MH. Assessment of two flexible and compatible snp genotyping platforms: Taqman snp genotyping assays and the snplex genotyping system. *Mutat Res/Fundamental Mol Mech Mutagen.* 2005;573(1):111–35.
- Gabriel S, Ziaugra L, Tabbaa D. Snp genotyping using the sequenom massarray iplex platform. *Current protocols in human genetics.* 2009;2: 2–12.
- Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, Guiducci C, Perola M, Jula A, Sinisalo J, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. *The Lancet.* 2010;376(9750):1393–400.
- Krawczyk M, Müllenbach R, Weber SN, Zimmer V, Lammert F. Genome-wide association studies and genetic risk assessment of liver diseases. *Nat Rev Gastroenterol Hepatol.* 2010;7(12):669–81.
- Hoang V, Thu P, Ambroise J, Dekairelle AF, Durant JF, Butoescu V, et al. Comparative pharmacogenetic analysis of risk polymorphisms in caucasian and vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome? *Br J Clin Pharmacol.* 2015;79(3): 429–40.